Express Scripts pulls Caremark bid from FTC
Executive Summary
Caremark is calling a legal maneuver by Express Scripts a ploy to avoid receiving additional Federal Trade Commission scrutiny of its hostile takeover bid for the rival pharmacy benefit manager (1"The Pink Sheet" Jan. 1, 2007, p. 3). By withdrawing its application for antitrust clearance for its proposed takeover of Caremark and then refiling the request on Feb. 6, Express Scripts says it will have 30 more days to discuss the transaction with FTC staff and avoid an agency request for additional information. The maneuver confirms that federal and state regulators "have identified serious antitrust concerns that, at a minimum, will require in-depth investigation," Caremark's other suitor CVS says. Caremark and CVS received FTC approval for their negotiated merger in December; their stockholders meet to vote on the deal on Feb. 20 and Feb. 23, respectively...
You may also be interested in...
Express Scripts Makes Hostile Bid For Caremark, But Faces CVS, FTC Hurdles
Express Scripts will work to characterize the pharmacy benefit management marketplace as being composed of more players than the "big three" independent PBMs in attempting to secure Federal Trade Commission clearance of its proposed acquisition of Caremark, CEO George Paz indicated
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.